ARTICLE | Clinical News
Cx601: Phase IIa data
February 21, 2011 8:00 AM UTC
Data from 22 evaluable patients in a Spanish Phase IIa trial showed that Cx601 was safe with only 5 patients experiencing adverse events considered potentially related to treatment. Additionally, Cx60...